[
  {
    "ts": null,
    "headline": "J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contract",
    "summary": "Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous settlement.",
    "url": "https://finnhub.io/api/news?id=10ed8923d37fce488cb0faa329b20d8bd88acbe9afc466657528b6b67babc328",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740526952,
      "headline": "J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contract",
      "id": 132902102,
      "image": "https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/02/shutterstock_2055997766.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous settlement.",
      "url": "https://finnhub.io/api/news?id=10ed8923d37fce488cb0faa329b20d8bd88acbe9afc466657528b6b67babc328"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note",
    "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.",
    "url": "https://finnhub.io/api/news?id=3f83e663933ff7d03d3933d2e3b6908e95d4fa21178297b823b4eb2226557eb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740523531,
      "headline": "Johnson & Johnson (JNJ) Ascends While Market Falls: Some Facts to Note",
      "id": 132902103,
      "image": "https://media.zenfs.com/en/zacks.com/17a4db66bb13bdabcbf848550a6ea15a",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In the closing of the recent trading day, Johnson & Johnson (JNJ) stood at $166.09, denoting a +1.44% change from the preceding trading day.",
      "url": "https://finnhub.io/api/news?id=3f83e663933ff7d03d3933d2e3b6908e95d4fa21178297b823b4eb2226557eb3"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Should Be Hurting. How the Sector Became This Year’s Top Performer.",
    "summary": "Healthcare Stocks Should Be Hurting. How the Sector Became This Year’s Top Performer.",
    "url": "https://finnhub.io/api/news?id=8833f98acfa862636e1dce43c993c99937aee464d76cc2b2afdacba07a93c573",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740500160,
      "headline": "Healthcare Stocks Should Be Hurting. How the Sector Became This Year’s Top Performer.",
      "id": 132881966,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Healthcare Stocks Should Be Hurting. How the Sector Became This Year’s Top Performer.",
      "url": "https://finnhub.io/api/news?id=8833f98acfa862636e1dce43c993c99937aee464d76cc2b2afdacba07a93c573"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Ranked 4th Best S&P 500 Dividend Aristocrat According to Hedge Funds",
    "summary": "We recently published a list of S&P 500 Dividend Aristocrats List: Sorted By Hedge Fund Sentiment. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other S&P 500 dividend aristocrats sorted by hedge fund sentiment. Dividend Aristocrats are companies that have consistently increased their dividend payments […]",
    "url": "https://finnhub.io/api/news?id=8c534c0835c136112dc2b59598a3522e576b92a60d389c1584884859a4ec0dc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740494627,
      "headline": "Johnson & Johnson (JNJ) Ranked 4th Best S&P 500 Dividend Aristocrat According to Hedge Funds",
      "id": 132902104,
      "image": "https://s.yimg.com/ny/api/res/1.2/DBFyZ0OZ_JyFkP8R8eQoiQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/f9ccf3c88c7274582ef19e20143427c2",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We recently published a list of S&P 500 Dividend Aristocrats List: Sorted By Hedge Fund Sentiment. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other S&P 500 dividend aristocrats sorted by hedge fund sentiment. Dividend Aristocrats are companies that have consistently increased their dividend payments […]",
      "url": "https://finnhub.io/api/news?id=8c534c0835c136112dc2b59598a3522e576b92a60d389c1584884859a4ec0dc4"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s potential neurovascular exit: implications for market dynamics",
    "summary": "The neurovascular market, estimated at $4.2bn in 2024 by GlobalData, is becoming increasingly specialised and competitive.",
    "url": "https://finnhub.io/api/news?id=3a2b3db73f08d02fb1f17a999c21bb091a5230c03a844a6ddac2e6218a1fe0ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740483536,
      "headline": "J&J’s potential neurovascular exit: implications for market dynamics",
      "id": 132902105,
      "image": "https://www.medicaldevice-network.com/wp-content/uploads/sites/23/2025/02/shutterstock_2008564148.jpg",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The neurovascular market, estimated at $4.2bn in 2024 by GlobalData, is becoming increasingly specialised and competitive.",
      "url": "https://finnhub.io/api/news?id=3a2b3db73f08d02fb1f17a999c21bb091a5230c03a844a6ddac2e6218a1fe0ea"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
    "summary": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
    "url": "https://finnhub.io/api/news?id=8d842d83f6441922524668fd84310b88e154005d92e6ffaab42931a7a420916f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740477240,
      "headline": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
      "id": 132881609,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Hims & Hers Stumbles as GLP-1 Compounding Ends. Lilly Presses the Advantage.",
      "url": "https://finnhub.io/api/news?id=8d842d83f6441922524668fd84310b88e154005d92e6ffaab42931a7a420916f"
    }
  }
]